Oramed on go with late-stage studies on oral insulin

Oramed Pharmaceuticals (ORMP +8.6%) announces that it has concluded its End of Phase 2 meeting with the FDA regarding its oral insulin capsule (ORMD-0801) for type 2 diabetics.

The agency outlined its expectations for Phase 3 studies and potential marketing application.

In March, the company announced initial End-of-Phase 2 meeting with the FDA related to Chemistry, Manufacturing and Controls data

https://seekingalpha.com/news/3591435-oramed-on-go-late-stage-studies-on-oral-insulin